BCC 2021 | Next-generation antibody-drug conjugates in HER2+ breast cancer
Jean-Yves Pierga, MD, PhD, Institut Curie, Paris, France, discusses novel antibody-drug conjugates available for HER2+ breast cancer which has shown efficacy in metastatic patients. Prof. Pierga highlights the importance of moving these immune agents into earlier lines of treatment to improve the outcomes of patients with HER2+ breast cancer, as well investigational agents such as sacituzumab govitecan currently being evaluated in other subtypes including triple-negative breast cancer (TNBC) as well its potential in HER2-low expressing cancers. This interview took place during the 17th St. Gallen International Breast Cancer Conference.
Disclosures
Prof. Pierga reports the following disclosures: Roche, Pfizer, MSD, Astra-Zeneca, Daiichi Sankyo, Lilly, Amgen, Mundipharma, Novartis, Pierre Fabre Oncology, Seagen
